WA
ACAD icon

Whipplewood Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Whipplewood Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.57K Hold
141
– – ﹤0.01% 359
2026
Q1 		$3.14K Buy
+141
New +$3.37K ﹤0.01% 696
2025
Q3 		– Sell
-171
Closed -$3.69K – 299
2025
Q2 		$3.69K Buy
+171
New +$3.18K ﹤0.01% 753

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Whipplewood Advisors's ACAD Position: Q2 2026 in Review

Whipplewood Advisors held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2026 at 141 shares worth $3.57K. The position accounts for ﹤0.01% of the portfolio, ranked #359.

Whipplewood Advisors first reported a position in ACAD in Q2 2025 and has held it in 3 quarters since. The position peaked at $3.69K in Q2 2025. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Whipplewood Advisors held 141 shares of Acadia Pharmaceuticals worth $3.57K as of Q2 2026.
  • Whipplewood Advisors left its Acadia Pharmaceuticals share count unchanged in Q2 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of Whipplewood Advisors's portfolio in Q2 2026, its #359 holding.
  • Whipplewood Advisors first reported a position in Acadia Pharmaceuticals in Q2 2025 and has held it in 3 quarters since.
  • Whipplewood Advisors's Acadia Pharmaceuticals position peaked at $3.69K in Q2 2025.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Whipplewood Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.